Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements. This article only introduces drugs related to healthcare and is not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
On January 12, 2026, CARsgen Therapeutics (Stock Code: 2171.HK), a biopharmaceutical company focused on developing innovative CAR-T cell therapies, and Dispatch Bio, a biotechnology company utilizing its first-in-class Flare platform to develop off-the-shelf treatments for solid tumors, announced a clinical collaboration to initiate a Phase I clinical trial in China in 2026.The trial will evaluate the application of the combination therapy DISP-11 in patients with solid tumors. This combination therapy consists of an investigational therapy (including its novel tumor-specific virus DV-10) developed by Dispatch Bio's proprietary Flare platform and CARsgen Pharma's BCMA-targeted autologous CAR-T cell product, Zekelc® (Zevorcabtagene Autoleucel Injection, product code: CT053). Zekelc® has been approved by China’s National Medical Products Administration (NMPA) for the treatment of multiple myeloma.Dr. Zonghai Li, Founder, Chairman of the Board, CEO and Chief Scientific Officer of CARsgen Therapeutics, said: "CARsgen Therapeutics is always committed to improving treatment prospects for patients with solid tumors by exploring the potential of CAR-T technology. Dispatch Bio's Flare platform provides us with a differentiated and highly complementary strategy, which is expected to further broaden the application scenarios of CAR-T therapy, especially for solid tumors lacking specific targets. We are very pleased to join hands in exploring this combination therapy, which is an important step in our continuous efforts to bring tangible clinical benefits to patients."In the studies conducted under this program, patients with solid tumors of epithelial origin (accounting for approximately 90% of all solid tumors) will first receive DV-10 treatment, followed by Zykadia® treatment.Dr. Sabah Oney, CEO of Dispatch Biotherapeutics, stated: "We are committed to expanding the reach of the Flare platform, and this collaboration marks a crucial step in regions with efficient, high-impact oncology R&D and significant unmet medical needs. The rigorous scientific approach and rapid clinical advancement capabilities of CARsgen Therapeutics make them an ideal partner for us. As our second collaboration with a company possessing commercialized CAR-T therapy, this partnership further strengthens industry confidence in the application of the Flare platform across various immunotherapies and helps shape our global development strategy."Source: Carsgen Therapeutics
Mastering CAR-T Therapy, Stem Cell Therapy, Gene
Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
